Opinion

Video

AYA ALL: Overview and Risk Stratification

Author(s):

Michael R. Grunwald, MD, FACP,Kelly Weaver, NP, DNP

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

Video content above is prompted by the following questions:

  • How is ALL risk stratified?
    • Which patient risk factors are considered?
    • Is there one standard model used?
    • What defines low-standard risk vs high risk?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Farrukh Awan, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
Related Content
Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 28th 2024

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Alex F. Herrera, MD
October 25th 2024

Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Paula G. O’Connor, MD, chief medical officer, Nurix Therapeutics
October 22nd 2024

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research